Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus‐related advanced hepatocellular carcinoma

Shin, Hyun Soo; Kim, Seung Up; Park, Jun Yong; Han, Kwang Hyub; Chon, Chae Yoon; Baatarkhuu, Oidov; Ahn, Sang Hoon

doi:10.1111/j.1440-1746.2012.07145.x

Cited by 14 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commonly used NAs include lamivudine (LAM), telbivudine, adefovir (ADV), entecavir (ETV), and tenofovir disoproxil fumarate (TDF). Different NAs seem to have a similar antiviral effect in HBVrelated HCC patients [62]. Less selective NAs, such as gemcitabine and 5-FU, are used as anti-tumor chemotherapy medications.…”

Section: Antiviral Treatment Medicationsmentioning

confidence: 99%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Section: Antiviral Treatment Medicationsmentioning

confidence: 99%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

“…Antiviral agents, such as lamivudine and adefovir have been found to improve cirrhotic liver function in some studies (Aspinall, et al 2011) but have not been shown to have anti-carcenogenic effects in other studies (Kwon and Lok 2011; Peng, et al 2012). In addition, there is evidence that these anti-viral agents have little effect on survival of patients with advanced-stage disease (Shin, et al 2012) or on disease recurrence after hepatectomy for HCC (Chan, et al 2011). …”

Section: Introductionmentioning

confidence: 99%

Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis

Lung¹,

Lai²,

Yeh³

et al. 2014

Endocrine-Related Cancer

145

114

View full text Add to dashboard Cite

Summary Androgen/androgen receptor (AR) signaling plays important roles in normal liver function and in progression of liver diseases. In studies of non-cancerous liver diseases, AR knockout mouse models of liver disease have revealed that androgen/AR signaling suppresses the development of steatosis, virus-related hepatitis, and cirrhosis. In addition, studies have shown that targeting AR in bone marrow-derived mesenchymal stem cells (BM-MSCs) improves their self-renewal and migration potentials, thereby increasing the efficacy of BM-MSC transplantation as a way to control the progression of cirrhosis. Androgen/AR signaling is known to be involved in the initiation of carcinogen- or Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, studies have demonstrated that AR, rather than androgen, plays the dominant role in cancer initiation. Therefore, targeting AR might be an appropriate therapy for patients with early-stage HCC. In contrast, androgen/AR signaling has been shown to suppress metastasis of HCC in patients with late-stage disease. In addition, there is evidence that therapy comprising Sorafenib and agents that enhance the functional expression of AR may suppress the progression of late-stage HCC.

show abstract

“…In a previous study, a less potent drug was reported to be equally effective as entecavir in advanced HCC patients 26,27. Shin et al 27.…”

Section: Discussionmentioning

confidence: 99%

“…Shin et al 27. compared 87 patients treated with lamivudine to 47 patients treated with entecavir, and they reported that the virological response and overall survival were similar.…”

Section: Discussionmentioning

confidence: 99%

“…compared entecavir and telbivudine in HBV-related advanced HCC patients, and they reported that telbivudine is highly cost-effective and should be considered as a first-line antiviral agent in patients with advanced HCC. Shin et al 27. also compared lamivudine versus entecavir in patients with HBV-related advanced HCC, and they reported that lamivudine is sufficient and cost-effective.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma

et al. 2016

View full text Add to dashboard Cite

Background/AimsAntiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in HBV-related HCC is not clear.MethodsA retrospective cohort of 451 newly diagnosed, HBV-related HCC patients without antiviral therapy at diagnosis, who started antiviral therapy with either entecavir (n=249) or lamivudine (n=202), were enrolled.ResultsThe median survival was longer for the entecavir group than for the lamivudine group, and lamivudine use (vs entecavir) was an independent factor for mortality (hazard ratio [HR], 1.49; p=0.002). Lamivudine use (vs entecavir) was an independent risk factor for new-onset hepatic decompensation (HR, 1.67; p=0.010) in 318 patients without previous hepatic decompensation, and it was also an independent risk factor for recurrence after curative therapy (HR, 1.84; p=0.002) in 117 patients who received curative therapy. The findings were similar in a propensity score-matched cohort.ConclusionsOverall survival, decompensation-free survival, and recurrence-free survival were better in the entecavir-treated patients than in the lamivudine treated-patients, indicating that the potent antiviral drug should be the preferred choice in HBV-related HCC patients.

show abstract

Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus‐related advanced hepatocellular carcinoma

Abstract: The antiviral efficacy of LAM and ETV was similar and the type of antiviral agent did not influence overall survival in patients with HBV-related advanced HCC. Thus, LAM, which is less expensive than ETV in Korea, might be sufficient to control HBV in these patients.

Cited by 14 publications

References 36 publications

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma

Contact Info

Product

Resources

About